A fifth case of limbic encephalitis associated with GAD antibodies and HHV-6 infection has been reported, this time in an immunocompetent woman with chromosomally integrated HHV-6, epilepsy, and psychosis. The patient’s condition improved (with a drop in GAD antibody titers and stabilization of psychotic symptoms) in response to three weeks of antiviral therapy but relapsed when antiviral therapy was withdrawn.
An Italian study on immunocompetent children with suspected CNS infections found HHV-6 and HHV-7 DNA in 4.2% and 4.8% of 304 cerebrospinal fluid (CSF) samples, respectively. Although once considered rare in the immunocompetent, recent studies with more sensitive methods have found HHV-6 in the CSF of 4-17% of immunocompetent children with seizures or suspected CNS infections.
Nicola Royle’s laboratory at the University of Leicester in the UK has reported that a ciHHV-6A patient with an HHV-8-negative primary effusion-like lymphoma had fully integrated genomes in the blood, but lost the integration in the tumor. Did the release of HHV-6A genomes play a role in tumor formation?
A group led by Ursula Gompels from the London School of Hygiene & Tropical Medicine, University of London, did next generation sequencing on three ciHHV6A cardiac patients and found superinfections of HHV-6A in two of the three. They characterized the first full genome sequence of ciHHV-6A and demonstrated the inherited ciHHV6 genome was similar but distinct from known exogenous (community acquired) strains of HHV-6A .
An interview with head researcher Nicola Royle, PhD: Should transplant patients & donors be screened?
HHV-6A infection of mesothelial cells causes HLA molecule modulation. This study demonstrates, for the first time, that human mesothelial cells are susceptible to HHV-6A infection. They also show that the virus causes modulated HLA expression on the cell surface, inducing the de novo expression of HLA class II and HLA-G
Congratulations to Joshua Hill, MD, Acting Instructor at the University of Washington and Research Associate at the Fred Hutchinson Cancer Research Center, who has won a K23 grant from the National Institute of Allergy and Infectious Diseases to study HHV-6 in lower respiratory tract disease and chromosomally integrated HHV-6 after stem cell transplantation (SCT).
Investigators led by Eain Murphy of Cleveland Clinic have identified a viral microRNA (miRNA) for HHV-6A, named miR-U86, that targets the HHV-6A intermediate early gene U86.
Bhupesh Prusty and Thomas Rudel of University of Wuerzburg, Germany, in collaboration with Dr. Yasuko Mori of Japan, have shed new light on the long-standing mystery of HHV-6 cell tropsim.
The December 2014 issue of Current Opinions in Virology features a “Special Section on Roseoloviruses.” Top experts in the field contributed a set of 14 reviews that span a wide range of critical topics encompassing the molecular biology and the
A group from University College London and the University of Zambia has reported that 20.5% of hospitalized infants were positive for HHV-6B, second only to CMV (24.3%). In contrast to previous studies, HHV-6A was found in only 0.3% of patients.
Immunocompetent adults are not supposed to get HHV-6 encephalitis or status epilepticus (SE) and HHV-6 testing is rarely performed in these patients. A new case report from Baylor suggests that testing for HHV-6 in these patients may be worthwhile.
New details may help advance the field of HHV-6 immunotherapy.
New study shows HHV-6 may induce demyelination through both B and T-cell reaction. HHV-6 oligoclonal bands were also found in cases of clinically isolated syndrome.
Dr. Louis Flamand’s laboratory in Quebec, Canada, has published an article with evidence that points toward a detailed mechanism for inhibition of IL-2 gene expression by HHV-6.